Immacule Lifesciences is the fastest growing One Stop Solution for Injectable, from Development to commercial manufacturing of injectable in liquid in aqueous/non aqueous as well as in Lyophilized dosage forms in vial and ampoules in non-oncology space with robust capabilities for terminal sterilization as well as aseptically filled injectable.
With global footprint across countries, including the United States, Europe, Australia and other emerging markets, we are backward integrated in the pharmaceutical research and development alongside manufacturing complex injectable.
With 10+ ANDA approved and more than 15 under review with a pipeline of another 20+ ANDAs for US Market, we are capturing rapidly, the highly competitive sterile US market.
Immacule, in its newly acquired land has plans to fuel in USD50 million to expand its drug product manufacturing capacity, in turn serving the industry’s pipeline across “various modalities”. Specifically, the expansion will bring on new freeze-drying capacity, Prefilled syringe & Cartridge capacity as well as mark its entry into Oncology injections. In all, 3 new lines are planned which will further consolidate Immacule’s position in fill finish CDMO category for the global market.by January 2024.
On the current business front, Immacule will continue to focus on First to File 505 (b)(2), NCEs & complex generics niche products scale-up, exhibit batches & commercial manufacturing support services to its global clients.
Promoter & co-founder of Acme formulation & Acme Generics (renowned name in Indian pharmaceutical industry)
VISION
- To become a globally reputed company in supply of high quality innovative sterile drug products.
MISSION
- To develop, register & commercialize maximum generic sterile drug product across all regulated and emerging markets in world.
